2026-04-19T09:43:20Zhttps://recercat.cat/oai/requestoai:recercat.cat:11351/104082025-10-24T08:24:45Zcom_2072_378070com_2072_378040col_2072_378092
RECERCAT
author
Picola Brau, Natalia
author
Paesano, Nahuel
author
Ruiz Plazas, Xavier
author
Muñoz-Rivero, Marta V.
author
Muñoz-Rodriguez, Jesus
author
Celma, Ana
author
Morote Robles, Juan
2025-10-24T08:24:45Z
2025-10-24T08:24:45Z
2023-10-05T07:47:08Z2023-10-05T07:47:08Z2023-09-13
http://hdl.handle.net/11351/10408
Prostate biopsy concordance; Systematic biopsy; Targeted biopsyConcordancia de biopsia de próstata; Biopsia sistemática; Biopsia dirigidaConcordança de biòpsia de pròstata; Biòpsia sistemàtica; Biòpsia dirigidaThe primary objective of this study was to analyse the current accuracy of targeted and systematic prostate biopsies in detecting csPCa. A secondary objective was to determine whether there are factors predicting the finding of csPCa in targeted biopsies and, if so, to explore the utility of a predictive model for csPCa detection only in targeted biopsies. We analysed 2122 men with suspected PCa, serum PSA > 3 ng/mL, and/or a suspicious digital rectal examination (DRE), who underwent targeted and systematic biopsies between 2021 and 2022. CsPCa (grade group 2 or higher) was detected in 1026 men (48.4%). Discrepancies in csPCa detection in targeted and systematic biopsies were observed in 49.6%, with 13.9% of csPCa cases being detected only in systematic biopsies and 35.7% only in targeted biopsies. A predictive model for csPCa detection only in targeted biopsies was developed from the independent predictors age (years), prostate volume (mL), PI-RADS score (3 to 5), mpMRI Tesla (1.5 vs. 3.0), TRUS-MRI fusion image technique (cognitive vs. software), and prostate biopsy route (transrectal vs. transperineal). The csPCa discrimination ability of targeted biopsies showed an AUC of 0.741 (95% CI 0.721–0.762). The avoidance rate of systematic prostate biopsies went from 0.5% without missing csPCa to 18.3% missing 4.6% of csPCa cases. We conclude that the csPCa diagnostic accuracy of targeted biopsies is higher than that of systematic biopsies. However, a significant rate of csPCa remains detected only in systematic biopsies. A predictive model for the partial omission of systematic biopsies was developed.This research was funded by the Instituto de Salut Carlos III (SP) and the European Union, grant number PI20/01666.
Attribution 4.0 International http://creativecommons.org/licenses/by/4.0/ info:eu-repo/semantics/openAccess
Pròstata - Càncer - Diagnòstic
Biòpsia
ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Diagnostic Techniques and Procedures::Clinical Laboratory Techniques::Cytological Techniques::Cytodiagnosis::Biopsy
DISEASES::Neoplasms::Neoplasms by Site::Urogenital Neoplasms::Genital Neoplasms, Male::Prostatic Neoplasms
Other subheadings::Other subheadings::/diagnosis
TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::técnicas y procedimientos diagnósticos::técnicas de laboratorio clínico::técnicas citológicas::citodiagnóstico::biopsia
ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias urogenitales::neoplasias de los genitales masculinos::neoplasias de la próstata
Otros calificadores::Otros calificadores::/diagnóstico
A Diagnostic Accuracy Study of Targeted and Systematic Biopsies to Detect Clinically Significant Prostate Cancer, including a Model for the Partial Omission of Systematic Biopsies
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion